• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管肝动脉化疗栓塞术联合局部消融治疗肝细胞癌的现状。

Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma.

机构信息

Department of Interventional Radiology, First Affiliated Hospital of Soochow University, 188 Shizi Street, 215006, Suzhou, Jiangsu, People's Republic of China.

出版信息

Abdom Radiol (NY). 2019 Jun;44(6):2268-2275. doi: 10.1007/s00261-019-01943-2.

DOI:10.1007/s00261-019-01943-2
PMID:31016345
Abstract

PURPOSE OF REVIEW

To review the current status and ideal time interval of the combination therapy of transarterial chemoembolization (TACE) and local ablation for patients with HCCs.

RECENT FINDINGS

In recent years, local ablation has been proposed as an alternative curative treatment in the management of HCC. Additionally, many treatment options are available including TACE molecular targeted agents and immune checkpoint inhibitors. Similar overall survival rates and prognoses have been obtained with radiofrequency ablation (RFA) microwave ablation (MWA) and cryoablation for patients with HCCs up to 3 cm in diameter. Yet, MWA has shown superiority in treating large HCCs while cryoablation has several advantages compared with RFA or MWA. Furthermore, the treatment strategy of TACE combined with local ablation is widely accepted by many physicians in order to further increase the survival rate and improve the prognosis of patients with HCCs. However, the time interval between the two sessions of combination therapy remains uncertain in the current guidelines. Combination therapy of TACE and local ablation has advantages on survival and prognosis in patients with HCC compared with monotherapy. Good patient selection for the right modality needs to be carried out to guarantee the most efficacious treatment for HCC patients. Further studies are needed to find the ideal time interval between TACE and local ablation for HCC patients.

摘要

目的综述

讨论经动脉化疗栓塞(TACE)联合局部消融治疗肝细胞癌(HCC)的现状和理想间隔时间。

最近发现

近年来,局部消融已被提议作为 HCC 治疗的一种替代根治性治疗方法。此外,有许多治疗选择,包括 TACE 分子靶向药物和免疫检查点抑制剂。对于直径不超过 3cm 的 HCC 患者,射频消融(RFA)、微波消融(MWA)和冷冻消融的总生存率和预后相似。然而,MWA 在治疗大 HCC 方面具有优势,而冷冻消融与 RFA 或 MWA 相比具有几个优势。此外,TACE 联合局部消融的治疗策略被许多医生广泛接受,以进一步提高 HCC 患者的生存率和改善预后。然而,目前指南中仍不确定两种联合治疗方案之间的时间间隔。与单独治疗相比,TACE 联合局部消融治疗 HCC 患者在生存和预后方面具有优势。需要对患者进行良好的选择,以保证对 HCC 患者进行最有效的治疗。需要进一步的研究来确定 HCC 患者 TACE 和局部消融之间的理想间隔时间。

相似文献

1
Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma.经导管肝动脉化疗栓塞术联合局部消融治疗肝细胞癌的现状。
Abdom Radiol (NY). 2019 Jun;44(6):2268-2275. doi: 10.1007/s00261-019-01943-2.
2
Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone.与单纯经动脉化疗栓塞相比,联合经动脉化疗栓塞和微波消融可提高 3 至 5 厘米肝癌的局部肿瘤控制率。
Abdom Radiol (NY). 2018 Sep;43(9):2497-2504. doi: 10.1007/s00261-018-1464-9.
3
The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma.经动脉化疗栓塞联合射频消融或微波消融治疗肝细胞癌。
Anal Cell Pathol (Amst). 2019 Aug 26;2019:8619096. doi: 10.1155/2019/8619096. eCollection 2019.
4
Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.经动脉化疗栓塞联合微波消融与单纯经动脉化疗栓塞治疗大的单发或多结节性肝细胞癌的疗效和预后因素比较。
Korean J Radiol. 2018 Mar-Apr;19(2):237-246. doi: 10.3348/kjr.2018.19.2.237. Epub 2018 Feb 22.
5
Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.经动脉化疗栓塞联合射频消融治疗早期肝细胞癌。
Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112. Epub 2016 Feb 15.
6
Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.联合射频消融或微波消融与经动脉化疗栓塞治疗中期肝细胞癌可提高疗效而不增加并发症:系统评价和荟萃分析。
Int J Hyperthermia. 2022;39(1):455-465. doi: 10.1080/02656736.2022.2048095.
7
Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.早期肝细胞癌不适于超声引导射频消融治疗:单纯经动脉化疗栓塞治疗与联合经动脉化疗栓塞和射频消融治疗的比较。
Cardiovasc Intervent Radiol. 2016 Mar;39(3):417-25. doi: 10.1007/s00270-015-1194-0. Epub 2015 Aug 6.
8
Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.联合经动脉化疗栓塞和射频消融与射频消融单药治疗≤3cm 单发肝细胞癌的长期疗效:重点关注局部肿瘤进展。
Int J Hyperthermia. 2022;39(1):1-7. doi: 10.1080/02656736.2021.1998660.
9
Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.新辅助经动脉单纯化疗栓塞和药物洗脱微球化疗栓塞治疗肝细胞癌后射频消融与微波消融的比较
Curr Probl Diagn Radiol. 2017 Nov-Dec;46(6):402-409. doi: 10.1067/j.cpradiol.2017.02.006. Epub 2017 Feb 20.
10
Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.经动脉化疗栓塞联合射频消融与单纯经动脉化疗栓塞治疗手术切除后复发性肝细胞癌的长期疗效
Dig Dis Sci. 2020 Apr;65(4):1266-1275. doi: 10.1007/s10620-019-05733-0. Epub 2019 Jul 17.

引用本文的文献

1
Modern approach to hepatocellular carcinoma treatment.肝细胞癌治疗的现代方法。
World J Hepatol. 2025 Aug 27;17(8):107873. doi: 10.4254/wjh.v17.i8.107873.
2
Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma.经动脉化疗栓塞术(D-TACE)联合射频消融术(D-RFA)治疗不可切除性大肝细胞癌的疗效与安全性
Front Oncol. 2025 Jul 28;15:1530951. doi: 10.3389/fonc.2025.1530951. eCollection 2025.
3
Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.
核因子IA介导的晶状体蛋白αB转录调控抑制肝细胞癌进展。
Mol Clin Oncol. 2025 Jun 20;23(2):72. doi: 10.3892/mco.2025.2867. eCollection 2025 Aug.
4
Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer.抗生素对免疫检查点抑制剂治疗原发性肝癌疗效的影响。
Liver Res. 2022 Jun 2;6(3):175-180. doi: 10.1016/j.livres.2022.05.004. eCollection 2022 Sep.
5
Anatomic sub-segmentectomy with single-session combined transcatheter arterial embolization/microwave ablation for the treatment of hepatocellular carcinoma: preliminary results.单期联合经导管动脉栓塞/微波消融解剖性亚段切除术治疗肝细胞癌:初步结果
Abdom Radiol (NY). 2025 Feb 6. doi: 10.1007/s00261-024-04784-w.
6
The combination of transarterial chemoembolization and microwave ablation is superior to microwave ablation alone for liver metastases from colorectal cancer.经动脉化疗栓塞与微波消融联合应用治疗结直肠癌肝转移,疗效优于单纯微波消融。
J Cancer Res Clin Oncol. 2024 Oct 1;150(10):440. doi: 10.1007/s00432-024-05951-8.
7
Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms.天然产物对肝癌的治疗作用及其潜在机制。
Nutrients. 2024 May 27;16(11):1642. doi: 10.3390/nu16111642.
8
Ferroptosis targeting natural compounds as a promising approach for developing potent liver cancer agents.靶向铁死亡的天然化合物作为开发强效肝癌药物的一种有前景的方法。
Front Pharmacol. 2024 Apr 26;15:1399677. doi: 10.3389/fphar.2024.1399677. eCollection 2024.
9
Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.复发性肝细胞癌患者的治疗策略:消融及其联合模式。
J Cancer. 2024 Feb 25;15(8):2193-2205. doi: 10.7150/jca.93885. eCollection 2024.
10
Novel biomarker genes for the prediction of post-hepatectomy survival of patients with NAFLD-related hepatocellular carcinoma.用于预测非酒精性脂肪性肝病相关肝细胞癌患者肝切除术后生存的新型生物标志物基因。
Cancer Cell Int. 2023 Nov 10;23(1):269. doi: 10.1186/s12935-023-03106-2.